| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/04/2006 | US7070807 Administering polypeptide by injection; gene therapy |
| 07/04/2006 | US7070799 Method for administering insulin to the buccal region |
| 07/04/2006 | US7070793 Antigen protein and nucleic acid coding for said protein |
| 07/04/2006 | US7070791 Comprises genetically engineered bacteriophage polymerase for detection and treatment of microorganismal infections |
| 07/04/2006 | US7070785 Heat shock proteins for use in enhancing cellular factor production |
| 07/04/2006 | US7070784 Method for down-regulating GDF-8 activity using immunogenic GDF-8 analogues |
| 07/04/2006 | US7070783 DNA having a specific sequence encoding a receptor molecule that binds to tumor necrosis factor comprising two extracellular domains of tumor necrosis factor receptors linked to a polypeptide linker, which is covalently bonded to said extracellular domains via peptide bonds; autoimmune diseases and IBDs |
| 07/04/2006 | US7070781 Nontoxic mucosal adjuvant |
| 07/04/2006 | US7070780 Treatment of demyelinating autoimmune disease with ordered peptides |
| 07/04/2006 | US7070776 inhibiting an immune response by reacting B7 positive cells with an antibody which binds with B7 antigen having a specific amino acid sequence |
| 07/04/2006 | US7070775 Recombinant A2-specific TNFα specific antibodies |
| 07/04/2006 | US7070774 Antibodies that bind testis-specific insulin homolog polypeptides |
| 07/04/2006 | US7070773 Blends of microbiocides and enzyme; nontoxic, corrosion resistance, nonflammable |
| 07/04/2006 | CA2396674C Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein |
| 07/04/2006 | CA2344318C Methods for administration of antibiotics |
| 07/04/2006 | CA2319544C Bibapcitide-based pharmaceutical compositions for imaging and treating thrombi |
| 07/04/2006 | CA2245554C Method for the production of rdspa .alpha.1 |
| 06/29/2006 | WO2006069371A1 A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis |
| 06/29/2006 | WO2006069329A2 Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis |
| 06/29/2006 | WO2006069253A2 Trefoil factors and methods of treating proliferation disorders using same |
| 06/29/2006 | WO2006069220A2 Modified human growth hormone |
| 06/29/2006 | WO2006069198A1 Flagellin related polypeptides and uses thereof |
| 06/29/2006 | WO2006069029A1 Purified rhigf-i/rhigfbp-3 complexes and their method of manufacture |
| 06/29/2006 | WO2006069001A2 Structural requirements for stat3 binding and recruitment to phosphototyrosine ligands |
| 06/29/2006 | WO2006068910A1 Glp-1 analog fusion protein formulations |
| 06/29/2006 | WO2006068867A1 Combination therapy for b cell disorders |
| 06/29/2006 | WO2006068822A1 Notch receptor agonists and uses |
| 06/29/2006 | WO2006068768A2 Methods and compositions for treating conditions |
| 06/29/2006 | WO2006068713A2 3,3'-diindolylmethane immune activating compositions |
| 06/29/2006 | WO2006068668A2 Compositions and methods for modulating calcium flux, glucose homeostasis and apoptosis |
| 06/29/2006 | WO2006068326A1 Novel polypeptide and the use thereof |
| 06/29/2006 | WO2006067920A1 Pharmaceutical for bone marrow stem cell transplantation therapy |
| 06/29/2006 | WO2006067856A1 Functional food or pharmaceutical and process for producing the same |
| 06/29/2006 | WO2006067807A1 Pharmaceutical composition for the treatment of invasive pulmonary aspergillosis |
| 06/29/2006 | WO2006067506A2 Hiv resistance genes |
| 06/29/2006 | WO2006067402A2 Agents inibiting the cathelin-like protein cap18/ll-37 |
| 06/29/2006 | WO2006067332A1 Use of botulinum toxin for prolonged local desensitization |
| 06/29/2006 | WO2006067210A1 Bcma polypeptides and uses thereof |
| 06/29/2006 | WO2006067141A1 Cladribine regimen for treating multiple sclerosis |
| 06/29/2006 | WO2006067091A1 Myd88 homodimerization inhibitors |
| 06/29/2006 | WO2006066960A1 Variant tfpi with increased anti-thrombotic activity |
| 06/29/2006 | WO2006066878A1 Prevention of thrombus formation and/or stabilization |
| 06/29/2006 | WO2006066599A2 Mas related g protein coupled receptors as drug targets |
| 06/29/2006 | WO2006066595A2 Recombinant production of serum albumin |
| 06/29/2006 | WO2006066483A1 Adhesion preventing biologic film for tendon ligament and its application |
| 06/29/2006 | WO2006066463A1 Receptor-selective lymphotoxin deviants |
| 06/29/2006 | WO2006066404A1 Therapeutic nutrient compositions or combinations and methods of their use |
| 06/29/2006 | WO2006066361A1 Method of treatment or prophylaxis |
| 06/29/2006 | WO2006066355A1 Chitin-binding peptides |
| 06/29/2006 | WO2006066334A1 Potassium channels in human heart |
| 06/29/2006 | WO2006066323A1 Formulations and treatments for trichology |
| 06/29/2006 | WO2006066317A1 Controlled release of biological entities |
| 06/29/2006 | WO2006054278A3 Variants of pigment epithelium derived factor and uses thereof |
| 06/29/2006 | WO2006042558A3 Group 2 mite polypeptide variants |
| 06/29/2006 | WO2006036465A9 Compositions and methods for treating cystic fibrosis |
| 06/29/2006 | WO2006021893A3 Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, fn staphylococcus aureus |
| 06/29/2006 | WO2006014466A3 Novel carbamylated epo and method for its production |
| 06/29/2006 | WO2005118782A3 Methods of promoting cardiac cell proliferation |
| 06/29/2006 | WO2005118620A3 Methods for preparing internally constraied peptides and peptidomimetics |
| 06/29/2006 | WO2005117848A3 Vascular targets for detecting, imaging and treating neoplasia or neovasculature |
| 06/29/2006 | WO2005115480A3 Modified protein kinase a-specific oligonucleotides and methods of their use |
| 06/29/2006 | WO2005110338A3 Identification of surface-associated antigens for tumor diagnosis and therapy |
| 06/29/2006 | WO2005107730A3 Cysteamines for treating complications of hypercholesterolemia and diabetes |
| 06/29/2006 | WO2005087793A3 Immunostimulatory compositions and uses thereof |
| 06/29/2006 | WO2005062864A3 Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
| 06/29/2006 | WO2005051418A3 Pharmaceutical formulations for the sustained release of interleukins and therapeutic applications thereof |
| 06/29/2006 | WO2005019242A8 Recombinant expression of the hag1 antimicrobial peptide: use as fusion partner for the expression of alpha helical antimicrobial peptides |
| 06/29/2006 | WO2005001092A3 Compositions and methods for diagnosing and treating cancers |
| 06/29/2006 | WO2004112693A3 Tissue protective cytokines with an extended therapeutic window |
| 06/29/2006 | WO2004093782A3 Tumor cytotoxicity induced by modulators of the cxcr4 receptor |
| 06/29/2006 | WO2004019880A3 Aw755252-interacting proteins and use thereof |
| 06/29/2006 | WO2004002412A3 A method and composition to elicit an effective autologous antitumoral immune response in a patient |
| 06/29/2006 | US20060143732 Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes |
| 06/29/2006 | US20060142557 2'-deoxy-2'alkylnucleotide containing nucleic acid |
| 06/29/2006 | US20060142556 Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| 06/29/2006 | US20060142394 Use of proteases for decomposing allergens |
| 06/29/2006 | US20060142264 Novel amide derivatives |
| 06/29/2006 | US20060142236 Antisense oligonucleotide modulation of raf gene expression |
| 06/29/2006 | US20060142231 DNA damage repair inhibitors for treatment of cancer |
| 06/29/2006 | US20060142229 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
| 06/29/2006 | US20060142225 siNA molecule comprising a double-stranded structure that down-regulates expression of cyclin dependent kinase-2 (CDK2) , wherein said siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference |
| 06/29/2006 | US20060142222 Novel gene relating to fibrotic conditions |
| 06/29/2006 | US20060142220 Protein modification |
| 06/29/2006 | US20060142219 Pharmaceutical compositions comprising an hiv envelope protein and cd4 |
| 06/29/2006 | US20060142218 Method of controlling telomere length |
| 06/29/2006 | US20060142205 Compositions capable of reducing elevated blood urea concentration |
| 06/29/2006 | US20060142204 Pyrrolidine derivatives for use in treating heaptitis c virus infection |
| 06/29/2006 | US20060142203 Antiproliferative agents; angiogenese inhibitors; antiinflammatory agents; anticancer agents |
| 06/29/2006 | US20060142202 Compositions and methods for targeted delivery of immune response modifiers |
| 06/29/2006 | US20060142201 amino acid sequence containing Xaa1 Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3 where Xaa1 is a N-terminal pyroglutamate (pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is Asn or a deletion; prophylaxis; neuropathic pain, inflammation, incontinence, cardiovascular conditions |
| 06/29/2006 | US20060142200 Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia |
| 06/29/2006 | US20060142199 CD-44 like protein |
| 06/29/2006 | US20060142198 Compositions for treating wounds and processes for their preparation |
| 06/29/2006 | US20060142197 TNF receptor and steroid hormone in a combined therapy |
| 06/29/2006 | US20060142196 Soluble GDNFR (Glial-cell Derived Neurotrophic Factor) that retains both ligand binding, and receptor signaling function (via Ret receptor tyrosine kinase) used to impart, restore, or enhance GDNFR alpha -ligand (preferably GDNF) responsiveness to cells; kidney diseases |
| 06/29/2006 | US20060142195 Non-neurotoxic plasminogen activating factors for treating of stroke |
| 06/29/2006 | US20060142194 Methods and compounds for treating brain amyloidosis |
| 06/29/2006 | US20060142193 Selective inhibition of rock1 in cardiac therapy |
| 06/29/2006 | US20060142192 Soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners and methods of using in inflammation |
| 06/29/2006 | US20060142191 Macular degeneration, choroidal or retinal neovascularization, or ocular inflammation; administering a poxvirus viral complement interfering protein (VCIP) |